CAS Medical Systems, Inc. Announces FORE-SIGHT Study to be Published in the Journal of Perinatology
Branford, Conn. – January 29, 2009 – CAS Medical Systems, Inc. (NasdaqGM: CASM), a leader in non-invasive monitoring that is vital to patient care, today announced the publication of a clinical study in the Journal of Perinatology utilizing its FORE-SIGHT® Absolute Cerebral Oximeter.
The study, entitled “Neonatal cerebral oximetry monitoring during ECMO cannulation,” is authored by JC Fenik and K. Rais-Bahrami, both of the Department of Neonatology at Children’s National Medical Center, Washington, DC and the Department of Neonatology at The George Washington University School of Medicine, Washington, DC. The purpose of the study was to monitor changes in cerebral perfusion with FORE-SIGHT cerebral oximetry before, during and after surgery to prepare neonatal patients for extracorporeal membrane oxygenation (ECMO) therapy. The study concludes that 70% of the infants studied do experience cerebral desaturations during cannulation for ECMO and that cerebral oximetry is “a useful bedside tool for management of critically ill neonates.”
Andrew E. Kersey, President and Chief Executive Officer stated, “This study is further evidence of the FORE-SIGHT Absolute Cerebral Oximeter’s value and reliability in this critical neonatal clinical setting. The use of FORE-SIGHT is of particular importance before, during and after surgery where traditional pulse oximetry may not be reliable, and previous generation cerebral oximeters provided trend-only information.
“In addition to this study, CASMED is expecting publication early this year of various additional clinical research supporting the use and benefits of the FORE-SIGHT Absolute Cerebral Oximeter in both the neonatal and adult arenas. We remain pleased with the growing market interest in FORE-SIGHT. Over the next month, we are exhibiting the FORE-SIGHT monitoring system at two key forums - the 4th International Conference on Brain Monitoring and Neuroprotection in the Newborn and the 25th Annual CNMC Symposium on ECMO & Advanced Therapies for Respiratory Failure.”
The Fenik, Rais-Bahrami study is available as an advance online publication of the Journal of Perinatology on the journal’s website (www.nature.com/jp). A link to the abstract is available in the Absolute Clinical Evidence section at www.casmed.com/foresight.
About CASMED® - Monitoring What’s Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company’s FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company’s product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs and cardio-respiratory monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com.
Company Contacts
CAS Medical Systems, Inc.
Susan Carron
Director of Corporate Communications
203-488-6056
ir@casmed.com
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2007 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
# # #
